Pralsetinib’s 2026 Phase 3 Data: Efficacy, Safety and Intermediate Control

Pralsetinib improved progression-free survival in the 2026 AcceleRET-Lung Phase 3 study, but infection findings and early termination require balanced interpretation. Public patents also highlight the importance of controlling a key chiral amine intermediate.

A randomized Phase 3 result can change how an established targeted therapy is understood, but it should not be reduced to a positive headline. In 2026, investigators reported results from AcceleRET-Lung, a study comparing pralsetinib with platinum-based standard-of-care therapy in previously untreated, RET fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC).

The findings add important comparative evidence for pralsetinib, which had already received regular FDA approval for metastatic RET fusion-positive NSCLC in 2023. They also offer a useful manufacturing lesson: the performance of a complex small-molecule medicine ultimately depends on controlled chemistry, including the identity and stereochemical integrity of its intermediates.

What the Phase 3 Study Reported

AcceleRET-Lung was an open-label study conducted at 74 sites in 22 countries. The intent-to-treat population included 223 patients: 110 were assigned to pralsetinib and 113 to standard-of-care therapy.

According to the 2026 Journal of Clinical Oncology meeting abstract, pralsetinib met the primary progression-free survival endpoint. Median progression-free survival was 18.7 months with pralsetinib and 9.0 months with standard care, corresponding to a hazard ratio of 0.59 and a reported P value of 0.003.

The reported overall response rate was also higher with pralsetinib: 65.5% versus 41.6%. Median duration of response was 20.6 months versus 9.7 months. These results support meaningful antitumor activity and a more durable response in the population studied.

Why the Result Requires a Balanced Reading

The efficacy results should be considered together with the study’s limitations and safety findings. The trial was terminated early on January 27, 2025. ClinicalTrials.gov attributes the termination to organizational and commercial decisions affecting development outside the United States and Greater China; it should not be presented as a demonstrated efficacy failure or as proof that a safety event caused the decision. Early termination can still reduce the amount and maturity of evidence available for some endpoints.

No overall-survival advantage was demonstrated in the reported analysis: the overall-survival hazard ratio was 1.09, with a P value of 0.742. The safety analysis also identified a higher incidence of infection with pralsetinib than with standard care, 71.3% versus 51.9%. Pneumonia occurred in 19.4% versus 5.8%, and opportunistic infections in 9.3% versus 1.0%. Eight deaths in the pralsetinib group, and none in the comparator group, were attributed to infection.

The investigators concluded that pralsetinib met the primary endpoint while emphasizing the need to monitor for infections. The study is therefore best described as a positive progression-free-survival result with important safety context—not as an unqualified clinical success.

Connecting Clinical Development to Publicly Disclosed Chemistry

Public patents disclose the chiral amine (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-amine in routes associated with RET inhibitors and pralsetinib preparation. In an originator patent, the amine is prepared through formation of a sulfinamide-controlled stereocenter followed by acidic deprotection. A later process patent identifies the corresponding chiral amine as an intermediate that is coupled with another advanced fragment during pralsetinib preparation.

Rlavie lists the dihydrochloride salt of this chiral amine as CAS 1980023-97-9. The shared chiral amine framework makes the product relevant to a discussion of pralsetinib route chemistry. However, this public structural relationship does not establish that Rlavie material was used in AcceleRET-Lung, supplied to the originator, qualified for a regulated manufacturing process, or used in the current commercial route. Patent examples also do not necessarily describe the route used in commercial production.

Why Intermediate Control Matters

The stereogenic center present in this amine is retained in the pralsetinib structure. Consequently, intermediate evaluation should extend beyond a general assay result. Depending on the intended application and development stage, relevant controls may include:

Confirmation of chemical identity and salt form
Enantiomeric purity using a suitable chiral method
Related-substance and process-impurity profiling
Water and residual-solvent determination
Understanding of salt stoichiometry and solid-state behavior
Traceability of starting materials and critical process changes
Batch-specific specifications supported by appropriate analytical methods

A CAS number or catalogue listing alone cannot establish suitability for a particular pharmaceutical process. Buyers should align specifications, methods, documentation and change-control expectations with the intended use. Where a route is still under development, early discussion of impurity fate and stereochemical risk can prevent later rework.

From Evidence to Reliable Chemistry

The 2026 AcceleRET-Lung data strengthen the comparative efficacy evidence for pralsetinib while also underscoring the need for careful safety interpretation. At the chemistry level, publicly disclosed routes illustrate how a defined chiral intermediate can contribute to the construction of a targeted small molecule.

For information about CAS 1980023-97-9, analytical documentation, custom synthesis or project-specific specifications, contact Rlavie. Technical and regulatory suitability should be evaluated for each intended application.

Sources

This article is an industry and process-chemistry overview. It does not constitute medical, regulatory or investment advice.